Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 6 of 26, showing 5 Applications out of 129 total, starting on record 26, ending on 30

# Protocol No Study Title Investigator(s) & Site(s)

26.

ECCT/23/06/09   Hibiscus Kid\'s Study
    A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Walter Otieno
2. Videlis Nduba
Site(s) in Kenya
1. Kombewa Clinical research Centre (Kisumu county)
2. KEMRI, Siaya Clinical Research Annex (Kisumu county)
 
View

27.

ECCT/23/06/08   TSCV3000
    Age-descending, randomized, placebo-controlled Phase 2 trial in three sites in sub-Saharan Africa to assess the safety and immunogenicity of a parenteral Trivalent Salmonella (S. Enteritidis/S. Typhimurium/S. Typhi Vi) Conjugate Vaccine (TSCV) versus placebo   
Principal Investigator(s)
1. RICHARD ONYANDO OMORE
Site(s) in Kenya
1. SIAYA COUNTY REFERRAL HOSPITAL (Siaya county)
2. ST. ELIZABETH LWAK HOSPITAL (Siaya county)
 
View

28.

ECCT/23/06/02   IMAGINE-TBM
    A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM).   
Principal Investigator(s)
1. Deborah Chepng\'eno Langat
Site(s) in Kenya
KEMRI/WRP CRC
 
View

29.

ECCT/23/05/06   Sildenafil citrate to improve
    Sildenafil citrate to improve maternal and neonatal outcomes in low-resource settings:    a randomized feasibility trial   
Principal Investigator(s)
1. Nora Switchenko
Site(s) in Kenya
NAKURU COUNTY REFERRAL AND TEACHING HOSPITAL
 
View

30.

ECCT/23/05/02   A5384
    A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM)   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
 
View